Michela Serresi

Michela Serresi

Auto-generated profile, based on publicly available information

Michela Serresi

Max Delbrück Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
MSMichela Serresi
Michela Serresi
SKSonia Kertalli
Sonia Kertalli
LLLifei Li
Lifei Li
MSMatthias Jürgen Schmitt
Matthias Jürgen Schmitt
YDYuliia Dramaretska
Yuliia Dramaretska
GGGaetano Gargiulo
Gaetano Gargiulo
Chromatin modulators with antagonistic functions on epithelial-mesenchymal interconversion regulate common pan-cancer genes.

4 April 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
GGGaetano Gargiulo
Gaetano Gargiulo
MSMichela Serresi
Michela Serresi
JMJean-Christophe Marine
Jean-Christophe Marine
Summary: Cancer is traditionally perceived through a genetic lens, with therapeutic strategies targeting oncogenic driver mutations. We advocate an overarching framework recognizing tumors as comprising driver, passenger, and trailer cell states: Tailoring therapies to simultaneously target driver genetics and cell states may enhance effectiveness and durability.

5 February 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
CCCarlos Company
Carlos Company
MSMatthias Jürgen Schmitt
Matthias Jürgen Schmitt
YDYuliia Dramaretska
Yuliia Dramaretska
MSMichela Serresi
Michela Serresi
SKSonia Kertalli
Sonia Kertalli
GGGaetano Gargiulo
Gaetano Gargiulo
Descriptive data are rapidly expanding in biomedical research. Instead, functional validation methods with sufficient complexity remain underdeveloped. Transcriptional reporters allow experimental characterization and manipulation of developmental and disease cell states, but their design lacks flexibility. Here, we report logical design of synthetic cis-regulatory DNA (LSD), a computational framework leveraging phenotypic biomarkers and trans-regulatory networks as input to design reporters marking the activity of selected cellular states and pathways. LSD uses bulk or single-cell biomarkers and a reference genome or custom cis-regulatory DNA datasets with user-defined boundary regions. By benchmarking validated reporters, we integrate LSD with a computational ranking of phenotypic specificity of putative cis-regulatory DNA. Experimentally, LSD-designed reporters targeting a wide range of cell states are functional without minimal promoters. Applied to broadly expressed genes from human and mouse tissues, LSD generates functional housekeeper-like sLCRs compatible with size constraints of AAV vectors for gene therapy applications. A mesenchymal glioblastoma reporter designed by LSD outperforms previously validated ones and canonical cell surface markers. In genome-scale CRISPRa screens, LSD facilitates the discovery of known and novel bona fide cell-state drivers. Thus, LSD captures core principles of cis-regulation and is broadly applicable to studying complex cell states and mechanisms of transcriptional regulation.

23 June 2023 in Science Advances
Verified
Journal Article
Open access
BJBen Jiang
Ben Jiang
MSMatthias Jürgen Schmitt
Matthias Jürgen Schmitt
URUlfert Rand
Ulfert Rand
CCCarlos Company
Carlos Company
YDYuliia Dramaretska
Yuliia Dramaretska
GGGaetano Gargiulo
Gaetano Gargiulo
Epithelial immune responses govern tissue homeostasis and offer drug targets against maladaptation. Here, we report a framework to generate drug discovery–ready reporters of cellular responses to viral infection. We reverse-engineered epithelial cell responses to SARS-CoV-2, the viral agent fueling the ongoing COVID-19 pandemic, and designed synthetic transcriptional reporters whose molecular logic comprises interferon-α/β/γ and NF-κB pathways. Such regulatory potential reflected single-cell data from experimental models to severe COVID-19 patient epithelial cells infected by SARS-CoV-2. SARS-CoV-2, type I interferons, and RIG-I drive reporter activation. Live-cell image–based phenotypic drug screens identified JAK inhibitors and DNA damage inducers as antagonistic modulators of epithelial cell response to interferons, RIG-I stimulation, and SARS-CoV-2. Synergistic or antagonistic modulation of the reporter by drugs underscored their mechanism of action and convergence on endogenous transcriptional programs. Our study describes a tool for dissecting antiviral responses to infection and sterile cues and rapidly discovering rational drug combinations for emerging viruses of concern.

30 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
MSMichela Serresi
Michela Serresi
ACAli Osman Cetin
Ali Osman Cetin
YDYuliia Dramaretska
Yuliia Dramaretska
SKSonia Kertalli
Sonia Kertalli
MSMatthias Jurgen Schmitt
Matthias Jurgen Schmitt
GGGaetano Gargiulo
Gaetano Gargiulo
Cancer cells display distinct, recurrent phenotypic cell states. Metastatic spreading correlates with tumor cell state evolution. However, the molecular mechanisms underlying metastasis remain elusive. Here, we demonstrate that the quantitative dosage of oncogenic KRAS drives lung adenocarcinoma progression and metastasis via the integration of external signaling and pioneer transcription factor dynamics into qualitative cell states. Combining mouse models, in vivo CRISPR activation screens, and fate mapping, we show that even mild transcriptional amplification of KRAS significantly fuels tumor progression and metastasis. Chromatin profiling and transcriptomics reveal that high and low KRAS dosages supersede and integrate inflammatory and TGFβ signaling to dictate mouse cancer cell states. Patient data show that KRAS dosages correlate with distinct survival outcomes, transcription factor activity, and cell states. Direct KRAS inhibition in xenografts limits the KRAS-high “proliferative” cell state but spares a minimal residual state mimicking the KRAS-low “ciliated-like” state. Thus, oncogenic KRAS dosage fuels tumor heterogeneity at the cell state level and drives a bimodal tumor evolution during metastasis, with implications for prognosis and treatment.

3 April 2023
Verified
Other
Open access
MSMatthias Jürgen Schmitt
Matthias Jürgen Schmitt
CCCarlos Company
Carlos Company
YDYuliia Dramaretska
Yuliia Dramaretska
IBIros Barozzi
Iros Barozzi
AGAndreas Göhrig
Andreas Göhrig
GGGaetano Gargiulo
Gaetano Gargiulo
Supplementary Figures, legends and References